



Internationally indexed journal

Indexed in Chemical Abstract Services (USA), Index copernicus, Ulrichs Directory of Periodicals, Google scholar, CABI ,DOAJ , PSOAR, EBSCO , Open J gate , Proquest , SCOPUS , EMBASE ,etc.



Rapid and Easy Publishing

The "International Journal of Pharma and Bio Sciences" (IJPBS) is an international journal in English published quarterly. The aim of IJPBS is to publish peer reviewed research and review articles rapidly without delay in the developing field of pharmaceutical and biological sciences



Pharmaceutical Sciences

- Pharmaceutics
- Novel drug delivery system
- Nanotechnology
- Pharmacology
- Pharmacognosy
- Analytical chemistry
- Pharmacy practice
- Pharmacogenomics



Biological Sciences

- Polymer sciences
- Biomaterial sciences
- Medicinal chemistry
- Natural chemistry
- Biotechnology
- Pharmacoinformatics
- Biopharmaceutics
- Biochemistry
- Biotechnology
- Bioinformatics
- Cell biology
- Microbiology
- Molecular biology
- Neurobiology
- Cytology
- Pathology
- Immunobiology

**Indexed in Elsevier Bibliographic Database
(Scopus and EMBASE)**

SCImago Journal Rank 0.288

Impact factor 5.121*

Chemical Abstracts
Service (www.cas.org)



A division of the American Chemical Society

CODEN IJPBJ2



Elsevier Bibliographic databases (Scopus & Embase)

SNIP value – 0.77

SJR - 0.288

IPP - 0.479

SNIP – Source normalised impact per paper

SJR – SCImago Journal rank

IPP – Impact per publication

Source – www.journalmetrics.com

(Powered by scopus (ELSEVIER))



LUND
UNIVERSITY



JACKSONVILLE STATE UNIVERSITY
Jacksonville State University
Houston Cole Library
USA (Alabama)



Oxford, United Kingdom

INDEX COPERNICUS
INTERNATIONAL

*And indexed/catalogued in
many more university*



*Instruction to Authors visit www.ijpbs.net

For any Queries, visit "contact" of www.ijpbs.net

**POSSIBLE EFFECTIVENESS OF ACYCLOVIR AS MEDICAL TREATMENT OPTION FOR VULVAL WARTS****DR.BUSHRA J. UMRAN***Babylon University College of Medicine- Gynaecology and Obstetrics Department Iraq.***ABSTRACT**

Infection with human papilloma virus is common, and associated with benign and malignant epithelial proliferations of skin and internal squamous mucosa. The mucosal human papilloma virus is oncogenic, and associated with 5 % of all cancers in men and women. A prospective study was done in Babylon Maternity and Paediatrics Teaching Hospital, for the period from February 2013 till February 2015, involved 240 women their ages ranged from 21 to 41 years. All of them were sexually active, married women, symptomatic, presented with multiple warty lesions in the vulva and eight had per-anal condylomata. History, examination, counselling and informed consent had been performed, then 120 women treated using acyclovir cream and 120 treated by electro-diathermy, 104 from 120(87.6%) completely cleared 5 days a week for 8 weeks application compared with 110 from 120 (91.7 %) in diathermy group. Six patients from acyclovir group had less response (5%) and ten got recurrence (8.3%) while the cautery group six had recurrence(5%),two got an infection (1.66%), one had depigmentation (0.83%) and one got scarring (0.83%). Although preventive vaccines might reduce human papilloma virus associated morbidity for future generations, those with active human papilloma virus disease still needs to be treated and treatment options either excision therapies, their aim to remove the lesion rather than target human papilloma viral infection while acyclovir target the virus itself.

KEY WORDS: *Human papilloma virus, Acyclovir.***DR.BUSHRA J. UMRAN***Babylon University College of Medicine- Gynaecology and
Obstetrics Department Iraq.****Corresponding author**

INTRODUCTION

The prevalence of genital human papilloma virus infections in the United States 10–20% of which clinical manifestations occur in 1% of the sexually active adult population, of which about 80% between the age of 17–33¹ Treatment can remove the warts, but they do not remove the virus, so it can recur in about 50–73%² or spontaneously regress with or without treatment¹ Some studies say that the virus remained in the body for a lifetime, while other studies using sensitive DNA techniques have shown that through immunological response the virus can either be cleared or suppressed to levels below what polymerase chain reaction (PCR) tests can measure. Genital warts are small fleshy growths that appear on or around the genital or anal area. In England, they are the second most common type of sexually transmitted infection after Chlamydia. They are a viral skin infection caused by the human papilloma virus. Around 90% of genital warts are caused by two strains of the virus, type 6 and type 11. It's a family of over 100 different strains of viruses; its spread occurs by skin-to-skin contact during vaginal or anal sex. It can be transmitted to others when warts present. Although it's possible to pass the virus before the warts have developed and after they have disappeared. Their diagnosis based on an examination. Skin biopsy is not necessary when a diagnosis can be made on clinical examination. Biopsy is required if the woman fails to respond to treatment or there is clinical suspicion of vulval cancer³. Treatment of genital warts can be physically ablative or topical agents, the ablative focused on removal of visible warts, but they may regress on their own without any therapy⁴. They do not reduce transmission of the underlying HPV infection, 80% of people with HPV will clear the infection within 18 months⁵ Warts can be treated depending on their number, sizes, or location. Treatments can potentially cause depigmentation, itching, pain, or scarring⁴. Physically ablative therapies are considered more effective at initial wart removal, but like all therapies have significant recurrence rates^{4,6}. They are appropriate for patients with fewer numbers and smaller warts⁶. Simple excision, such as with scissors under local anaesthesia, is highly effective⁴. Liquid nitrogen cryosurgery is performed in an office visit, at weekly intervals. It is effective, inexpensive, safe for pregnancy, and does not usually causes scarring⁴. Electro cauterization is procedure with a longer history of use, and is considered effective⁴. Laser ablation has less evidence for its use. It may be less effective than other ablative methods⁶. It is expensive, and used as a last resort⁷. Surgical procedures, performed under general anaesthesia, may be needed for larger or more extensive warts, or intra-anal warts⁴. It carries a greater risk of scarring than other methods⁸. Topical agents, like podophyllotoxin (podofilox) solution in a gel or cream can be used. It is safer and more effective than podophyllin although skin erosion and pain are more commonly reported than with imiquimod and sinecatechins⁹. Its use is cycled (2 times per day for 3 days then 4–7 days off). One review states that it should only be used for four cycles.^[10] Imiquimod (Aldara) is a topical immune response cream, applied to the affected area. It causes less local

irritation than podofilox but may cause fungal infections and flu-like symptoms⁹. Sinecatechins (Veregen and Polyphenon E) is an ointment of catechins (55% epigallocatechin gallate⁷ extracted from green tea and other components. Mode of action is undetermined¹¹. It appears to have higher clearance rates than podophyllotoxin and imiquimod and causes less local irritation, but clearance takes longer than with imiquimod⁹. Trichloroacetic acid is less effective than cryosurgery¹⁰, and is not recommended for use in the vagina, cervix, or urinary meatus⁷. Interferon can be used; it is effective, but it is also expensive and its effect is inconsistent¹⁰. A 5% 5-fluorouracil (5-FU) cream was used, but it is no longer considered an acceptable treatment due to the side-effects⁷. Podophyllin, podofilox and Isotretinoin should not be used during pregnancy, as they could cause birth defects in the foetus¹¹ Genital wart can be prevented by using human papilloma virus vaccine. Gardasil, is available for prevention of genital warts. It helps prevent infection from four types of HPV (types 6, 11, 16, and 18), which helps to prevent most cases of cervical cancer (caused by HPV 16 and 18) and genital warts (caused by HPV 6 and 11). Another vaccine, Cervarix, helps prevent infection from two types of HPV (types 16 and 18), thus it helps to prevent most cases of cervical cancer, but not genital warts¹². Human papillomavirus (HPV) is a DNA virus from the papillomavirus family that is capable of infecting humans. Like all papillomaviruses, HPVs establish productive infections only in keratinocytes of the skin or mucous membranes. Most HPV infections are subclinical and will cause no physical symptoms; however, in some people subclinical infections will be clinically evident and may cause benign papillomas such as warts or cancers of the cervix, vulva, vagina, oropharynx and anus¹³. Acyclovir (9-[2-hydroxyethoxymethyl] guanine) has proved to be a safe and effective agent for therapy of herpes simplex and varicella-zoster infections. It's availability in topical, oral, and intravenous preparations. Acyclovir must be phosphorylated by viral thymidine kinase in infected cells, where it then acts to inhibit viral DNA replication specifically. It's well absorbed and distributed, with cerebrospinal fluid levels 50% that of plasma. Clearance is almost entirely by the renal route, with a half-life of 20 hours in the anuric patient, its major adverse effect being transient serum creatinine elevations during high-dose intravenous use. Major uses include treatment of primary and recurrent genital herpes and herpes encephalitis and prophylaxis and therapy of mucocutaneous herpes and varicella-zoster infections in immunocompromised patients. Resistance to acyclovir in herpes simplex virus is rarely encountered¹⁴. Common adverse drug reactions ($\geq 1\%$ of patients) associated with systemic acyclovir therapy (oral or IV) include: nausea, vomiting, diarrhoea, encephalopathy (with IV use only), injection site reactions (with IV use only) and headache. In high doses, hallucinations have been reported. Infrequent adverse effects (0.1–1% of patients) include: agitation, vertigo, confusion, dizziness, oedema, arthralgia, sore throat, constipation, abdominal pain, hair loss, rash and weakness. Rare adverse effects ($< 0.1\%$ of patients) include: coma,

seizures, neutropenia, leukopenia, crystalluria, anorexia, fatigue, hepatitis, Stevens–Johnson syndrome, toxic epidermal necrolysis, thrombotic thrombocytopenic purpura and anaphylaxis¹⁵. Aciclovir classified as a Category B Drug¹⁶, It is recommended by the Centers for Disease Control and Prevention (CDC) for treatment of Varicella during pregnancy, especially during the second and third trimesters¹⁷.

MATERIALS AND METHODS


Our study was a prospective study, performed in an outpatient clinic in Babylon Maternity and Paediatrics Teaching Hospital for the period from February 2013 till February 2015, involved 240 women their ages ranged from 21 to 41 years with a mean (29.56±5.60) years old. All of them were sexually active married women symptomatic presented with multiple warty lesions diagnosed with vulval condylomata and eight had vulval with perianal condylomata. The Ethical Committee of College of Medicine had approved it. All women involved in the study after counselling the benefits and side effects of this medication gave informed consent for its use. Inclusion criteria were; women accepted to participate in the study, within the reproductive age group from (21 - 41) years, no history of previous use of medication to treat it. Exclusion criteria included; current pregnancy or suspicion of early pregnancy, lactation amenorrhea, a history of acute or chronic renal diseases, current use of chronic medications. A questionnaire was designed information included; demographic measurements (age, parity, weight, height, residence, education and occupation), medical history, drug intake, menstrual history, obstetrical history and contraception history and history of breast feeding. Difficulties were encountered while selecting the cases under study, the acceptance to participate in the study, the inclusion criteria, the type of medication to be used, the co-operation to re-attend back to the clinic later and to inability to visit the clinic in time for re-evaluation due to socioeconomic reason. During the

study period 265 women attended having symptomatic wart lesion, after counselling 240 women accepted to participate in the study and been followed up. Their phone number was taken. Detailed history taken. Height and body weight was measured as a baseline, BMI was then measured by the following equation $BMI = \text{weight (kg)} / \text{height}^2 (\text{m}^2)$. Overweight is considered when the body mass index is between 25.1kg/m² to 29.9kg/m², while a body mass index $\geq 30\text{kg/m}^2$ considered as obesity, both excluded in our study. Then been divided randomly into two groups. One hundred twenty women treated with electro-diathermy another 120 women received acyclovir ointment 5% w/w cream four times a day for five days a week. Maxim treatment duration was 8 weeks. ZOVIRAX is the brand name for acyclovir, a synthetic nucleoside analogue active against herpes viruses. ZOVIRAX Cream, 5% is a formulation for topical administration. The chemical name of acyclovir is 2-amino-1,9-dihydro-9-[(2-hydroxyethoxy)methyl]-6H-purin-6-one. Acyclovir is a white, crystalline powder with the molecular formula C₈H₁₁N₅O₃ and a molecular weight of 225. The maximum solubility in water at 37°C is 2.5 mg/mL. The pKa's of acyclovir are 2.27 and 9.25. Each gram of ZOVIRAX Cream, 5% contains 50 mg of acyclovir and the following inactive ingredients: cetostearyl alcohol, mineral oil, poloxamer 407, propylene glycol, sodium lauryl sulfate, water, and white petrolatum (Manufactured by GlaxoSmithKline Research Triangle Park, NC 27709 for BTA Pharmaceuticals, Inc. (subsidiary of Biovail Corporation) Bridgewater, NJ 08807 Made in India). To evaluate the safety and clinical efficacy, patients were examined and lesion areas checked on a weekly basis. All statistical analysis was done by using statistical package for social sciences (SPSS) version 21. Categorical data were described as count and percentage while numerical data were described as mean and standard error of mean. Comparisons between groups were made by using chi-square test or categorical data and t-test for numerical data. The lowest level of probability to be accepted equal or less than 0.05.

RESULTS

Distribution of Patients with Vulval Warts by Socio-Demographic Characteristics

Figure 1
Distribution of patients with vulval warts by residence



The overall mean age of patients with vulval warts was (29.56 ± 5.60) years old, (75.0%) of patients were from urban areas (Figure 1).

Figure 2
Distribution of patients with vulval warts by occupational status




Figure (2) show distribution of patients with vulval warts by occupational status, (54.2%) of patients was employed.

Figure 3
Distribution of patients with vulval warts by educational levels




Figure 3 shows the distribution of patients with vulval warts by educational levels, (43.3%) of patients were illiterate.

Distribution of Patients with Vulval Warts by Medical History

Table 1 shows the distribution of patients with vulval warts by medical history, (81.7%) of patients were multi-Para, (72.5%) of patients had more than five wart lesions. (56.7%) of patient was not use any contraception.

Table 1
Distribution of Patients with Vulval Warts by Medical History

Variable	Frequency (%)
Parity	44
Null-Para	(18.3%)
Multi-Para	196
	(81.7%)
Clinical presentation	174
> 5 wart lesions	(72.5%)
3-5 wart lesions	58
Vulval and peri-anal lesions	(24.2%)
	8 (3.3%)
Contraception	44
	(18.3%)
Combined oral contraceptive pills	34
Depo-provera injection	(14.2%)
Intrauterine contraceptive device	26
No contraception	(10.8%)
	136
	(56.7%)

Distribution of Patients with Vulval Warts by Acyclovir and Cautery Treatments

Figure 4 shows the Distribution of Patients with Vulval Warts by Acyclovir and Cautery Treatments, (86.7%) and (91.7%) of patients were cured by Acyclovir and

Cautery Treatments, respectively. Six patients from acyclovir group had less response (5%) and ten got recurrence (8.3%) while the cautery group six had recurrence(5%),two got infection (1.66%), one had depigmentation (0.83%) and one got scarring (0.83%).




Figure 4
Distribution of Patients with Vulval Warts by Acyclovir and Cautery Treatments

Associations of Acyclovir and Cautery Treatments with Patients Socio-Demographic Characteristics

Table 2 shows the Associations of Acyclovir and Cautery Treatments with Patients Socio-Demographic Characteristics, there were no significant associations of acyclovir and cautery treatments with patients' socio-demographic characteristics; p value ≤ 0.05 is significant.

Table 2
Associations of Acyclovir and Cautery Treatments with Patients Socio-Demographic Characteristics

Variable	Acyclovir Treatment		Cautery Treatment	
	Non-Cure (%)	Cure (%)	Non-Cure (%)	Cure (%)
Age group				
< 30 years	9 (56.3)	56 (53.8)	7 (70.0)	58 (52.7)
≥ 30 years	7 (43.7)	48 (46.2)	3 (30.0)	52 (47.3)
X ² value	0.032		1.102	
P value	0.857		0.294	
Residence				
Urban area	12 (75.0)	78 (75.0)	6 (60.0)	84 (76.4)
Rural area	4 (25.0)	26 (25.0)	4 (40.0)	26 (23.6)
X ² value	0.0		1.309	
P value	1.000		0.253	
Occupational status				
Employed	9 (56.3)	56 (53.8)	6 (60.0)	59 (53.6)
Non-Employed	7 (43.7)	48 (46.2)	4 (40.0)	51 (46.4)
X ² value	0.032		0.150	
P value	0.857		0.699	
Educational level				
Illiterate	4 (25.0)	48 (46.2)	1 (10.0)	51 (46.4)
Primary school	6 (37.5)	29 (27.9)	4 (40.0)	31 (28.2)
Secondary school	4 (25.0)	21 (20.2)	3 (30.0)	22 (20.0)
Higher education	2 (12.5)	6 (5.8)	2 (20.0)	6 (5.5)
X ² value	2.968		6.585	
P value	0.392		0.068	

Associations of Acyclovir and Cautery Treatments with Patients Medical History

Table 3 shows the Association of Acyclovir and Cautery Treatments with Patients medical history, there were significant associations of acyclovir and cautery treatments with clinical presentation and complication due to vulval warts treatment as well as using of contraception, p value ≤ 0.05 is significant.

Table 3
Associations of Acyclovir and Cautery Treatments with Patients Medical History

Variable	Acyclovir Treatment		Cautery Treatment	
	Non-Cure (%)	Cure (%)	Non-Cure (%)	Cure (%)
Parity				
Null-Para	3 (18.8)	19 (18.3)	3 (30.0)	19 (17.3)
Multi-Para	13 (81.2)	85 (81.7)	7 (70.0)	91 (82.7)
X ² value	0.002		0.992	
P value	0.963		0.319	
Clinical presentation				
> 5 wart lesions	5 (31.3)	82 (78.8)	0 (0.0)	87 (79.1)
3-5 wart lesions	9 (56.3)	20 (19.2)	8 (80.0)	21 (19.1)
Vulval and perianal lesions	2 (12.5)	2 (1.9)	2 (20.0)	2 (1.8)
X ² value	16.850		31.072	
P value	<0.001*		<0.001*	
Contraception				
Combined oral contraceptive pills	8 (50.0)	14 (13.5)	5 (50.0)	17 (15.5)
Depo-provera injection	3 (18.8)	14 (13.5)	2 (20.0)	15 (13.6)
Intrauterine contraceptive device	2 (12.4)	11 (10.6)	1 (10.0)	12 (10.9)
No contraception	3 (18.8)	65 (62.5)	2 (20.0)	66 (60.0)
X ² value	15.103		8.824	
P value	0.002*		0.032*	
Complication due to vulval warts tr.				
Yes	10 (62.5)	9 (8.7)	10 (100.0)	9 (8.2)
No	6 (37.5)	95 (91.3)	0 (0.0)	101 (91.8)
X ² value	30.170		57.990	
P value	<0.001*		<0.001*	

DISCUSSION

All women in this study attended the outpatient clinic worried from multiple growths developed first time in the vulval area most of them didn't know its nature .93.3% of these patients were illiterate or had a primary or secondary school educational level and they didn't know its nature or its consequences, and their ability to recover from it. They felt difficult to leave it without consultation. So we clarify it to them that it is a viral infection which needs treatment and it is necessary to follow up. Current treatments are still unsatisfactory due to low efficacy and recurrence rate. In spite of prophylactic vaccines have been recommended for adolescent women. Appropriate treatment modalities from ano-genital warts are needed because of unavailability of the vaccine especially in developing countries as in our country or its cost. We compared the use of acyclovir cream which acts on viral DNA. Human papilloma virus is DNA virus with diathermy treatment which aimed to remove the lesions in a randomised trial 104 from 120(87.6%) completely cleared 5 days a week for 8 weeks application compared with 110 from 120 (91.7 %) in diathermy group which ended in one session but had pain of burn and complications as infection, scarring and de-pigmentation. Of the remaining sixteen in the acyclovir group six responded to acyclovir but were not completely cured (5%) and ten got recurrence (8.3%). There are many studies used different options of treatment for genital warts, whether medical or excisional each had its advantages and disadvantages. A study by Friedman M. *et al*, used the immunomodulator ammonium trichloro- tellurate 15% w/w cream to clear vulval/peri-anal condylomata acuminata, (76%) patients were considered completely cleared. Complete cure was achieved in 35 of 44 (80%) patients with vulval condylomata and in 21 of 30 (70%) patients with peri-anal condylomata. No scarring of treated areas was observed. Complete cure was achieved within a time range of 10-109 days. The most frequent side-effects observed were mild-to-moderate

itching, soreness; burning and erythema while in our study no side effects from acyclovir application. In post-treatment follow up of up to 6 months, disease recurrence was observed in two patients (4%), at 105 and 144 days following completion of treatment¹⁸. Another study by Tatti S, *et al*, sinecatechins ointment 15% or 10% or vehicle (placebo) been used three times daily for a maximum of 16 weeks or until complete clearance of all warts: Complete clearance of all baseline and newly occurring warts was obtained in 57.2% and 56.3% of patients treated with sinecatechins ointment 15% and 10%, respectively, compared with 33.7% for vehicle (both P<.001). Significance was observed at weeks 4 and 6 and all subsequent visits. Numbers needed to treat were 4.3 and 4.4. Partial clearance rates of at least 50% were reported for 78.4% and 74.0% of patients in the sinecatechins ointment 15% and 10% groups compared with 51.5% of vehicle patients. During follow-up, recurrence of wart was observed in 6.5%, 8.3%, and 8.8% in the sinecatechins ointment 15% group, sinecatechins ointment 10% group, and vehicle patients, respectively. A total of 3.7%, 8.3%, and 0.0% developed new warts, respectively. A total of 87.7% and 87.3% of patients in the sinecatechins ointment 15% and 10% groups, and 72.1% of vehicle patients experienced application site reactions; 49.2%, 46.2%, and 65.4% of those, respectively, were mild or moderate¹⁹. Other study by Stockfleth E, *et al* showed About 78% of all patients treated with either Polyphenon E 15% or 10% ointment showed wart clearance rates of 50% or better. Less than 6% and 4% of patients in the Polyphenon E 15% and 10% ointment groups experienced wart recurrence during follow-up. Polyphenon E ointments demonstrated adverse effects being local application site reactions which were mild or moderate and local reactions declined during continued treatment²⁰. A study by Diamantis ML, *et al*, demonstrated that imiquimod 5% cream showed complete clearance of warts occurred in up to 50% of patients treated with imiquimod 5% cream applied once-daily, 3 times per

week for up to 16 weeks. Recurrence rates ranged from up to 19% at 3 months to 23% at 6 months²¹. Akhavan S, *etal* study included six groups 42 in each group. Women aged 20-50 years: the podophyllin-, imiquimod- and cryotherapy-treated groups, and another three groups receiving 8-week combination therapy of 400 mg oral zinc sulfate with one of the above treatments. Total of 228 patients were recruited and completed the study in six treatment groups. No significant difference was observed in the response to treatment among these groups. Relapse after 6 months was significantly higher in the podophyllin-, imiquimod- and cryotherapy-treated patients compared to patients receiving these treatments in combination with oral zinc sulphate²². Another study by R.J.C.Gilson, *etal*: compare the efficacy and safety of combination therapy with cryotherapy and podophyllotoxin 0.15% cream versus cryotherapy alone in the treatment of anogenital warts. A randomised, double-blind, multicentre controlled trial. Patients received podophyllotoxin cream or placebo twice daily for 3 days/week for up to 4 weeks, with weekly cryotherapy continued to week 12 if required. Further treatment from week 12 to 24 was discretionary 70 patients per group were randomly assigned and started treatment; 101 first-episode warts, 91 males. No treatment-related serious adverse events were reported. Follow-up at week 12 was 85%. By intention-to-treat analysis, clearances at 4 and 12 weeks were higher in the combination group (60.0% and 60.0%, respectively) than with cryotherapy alone (45.7%, 45.7%) although not statistically significant (RR 1.31, 95% CI 0.95 to 1.81). By week 24 there was no difference between the groups (68.6% and 64.3%, respectively; RR 1.07, CI 0.84 to 1.35). At week 4, wart clearance was higher in men (p=0.001) and those with a past history of warts (p=0.009), but these differences were not detected at week 12. There was some evidence for a higher relapse rate in the group receiving cryotherapy alone²³. A study by Panici, *etal* involved two hundred three patients their ages range (18- 45) years compared the use of systemic recombinant

interferon intramuscular, subcutaneous injection with electro diathermy coagulation after six months of end of treatment the overall complete and partial response was 70%, 57% and 82%. Fifteen and two in the cauterisation and interferon group respectively developed disease recurrence. All patients received interferon developed flu like illness for the first week and fatigue during the period of receiving the treatment²⁴. Excisional therapies, their aim to remove the lesion rather than specifically target HPV infection. Carrasco D, *etal* study found that Cytodestructive or surgical therapy for patients with anogenital warts is frequently associated with recurrence. In February 1997, the US Food and Drug Administration approved imiquimod as a 5% cream for the treatment of anogenital warts. Activity of the drug results primarily from interferon alfa and other cytokine induction in the skin. These cytokines stimulate several other aspects of the innate immune response. In addition, imiquimod stimulates acquired immunity, in particular the cellular arm that is important for control of viral infections and tumors. Published studies indicate that imiquimod results in complete clearance of warts in more than 50% of patients. Residual warts can be surgically excised. Their long-term follow-up (2 to 7 years) of patients who had a 16-week course of imiquimod cream with subsequent removal of remaining warts showed a much lower rate of recurrence in comparison with those patients who were treated with surgery alone. Therefore, treatment with imiquimod followed by excision of residual lesions may provide long-term clearance of anogenital warts in those patients in whom imiquimod monotherapy is insufficient²⁵.

CONCLUSION

Future therapies will be directly or indirectly antiviral, targeting HPV protein functions or enhancing the ability of the immune system to resolve infection or inducing an immune response against it.

REFERENCES

1. Scheinfeld N, Lehman DS "An evidence-based review of medical and surgical treatments of genital warts". *Dermatol. Online J.* 12 (3): 5 (2006).
2. M.K. Ramirez-Fort, F. Khan, P.L. Rady - Human papilloma virus Kraft Druck Ettlingen, Germany; p.209, 2014.
3. Wiley DJ, Douglas J, Beutner K, External genital warts: diagnosis, treatment, and prevention. *Clin Infect Dis.* 15;35(Suppl 2):S2,10-24,2002.
4. Lacey, C.J; Woodhall, SC; Wikstrom, A, European guideline for the management of anogenital warts. *Europ.Acad. Dermatol. And Venereo . J.* Mar.27(3) 2013.
5. Gormley, R.H; Kovarik, C.L. "Human papillomavirus-related genital disease in the immunocompromised host: Part I." *J. Am. Acad.Dermatol.* 66 (6): 867. June 2012.
6. Workowski, K; Berman, S. Sexually Transmitted Diseases Treatment Guidelines, (PDF). *United States Centers for Disease Control.* p. 70.-73, 2010.
7. Mayeaux E.J, Dunton C. "Modern management of external genital warts". *J Low Genit Tract Dis* 12 (3): 185-192. (July 2008).
8. Kodner C.M, Nasraty S. "Management of genital warts". *Am Fam Physician* 70 (12): 2335-2342. (December 2004).
9. Meltzer SM, Monk B.J, Tewari K.S (March 2009). "Green tea catechins for treatment of external genital warts". *Am. J. Obstet. Gynecol.* 200 (3): 233(March 2009).
10. Scheinfeld N, Lehman D.S (2006). "An evidence-based review of medical and surgical treatments of genital warts". *Dermatol. Online J.* 12 (3): 5. (2006).
11. Stockfleth E, Meyer T. The use of sinecatechins (polyphenon E) ointment for treatment of external genital warts: Expert Opin Biol Ther. *J.* 12(6):783-93, 2012.

12. Stern P.L, van der Burg S.H, Hampson I.N.. Therapy of human papillomavirus-related disease. *Vaccine*30 Suppl 5: 71–82. 2012; .
13. Stanley, Margaret A; Winder, David M; Sterling, Jane C; Goon, Peter KC (2012). "HPV infection, anal intra-epithelial neoplasia (AIN) and anal cancer: current issues". *BMC Cancer* 12 (1): 398. (2012)
14. Dorsky D.I, Crumpacker CS Drugs five years later: acyclovir; *Ann Intern Med.* Dec; 107(6):859-74.(1987)
15. G.C Cherfan,Dr. Muhammad Abdel Razzak,Mazen M. Hassan,GlaxoSmithKline. Zovirax® (acyclovir) prescribing information by the Manufacturer,Middle East Medical Index 28th ed. CCM Middle East,Greece,p572-575, 2006.
16. Wassilew S.W, Reimlinger S, Nasemann T. Epidemiology and prevention of vaccine-preventable diseases. 9th ed. Public Health Foundation; Jan: 171-92, 2006.
17. Friedman M.--- Bayer I. ---Letko I. --- Duvdevani R. Topical treatment for human papillomavirus – associated genital warts in humans with the novel tellurium immunomodulator AS101: assessment of its safety and efficacy *Br. J. Dermatol.* ISSN: 00070963 Year :2009 Volume:160 Issue : 2 Pages : 403-408 provider :Blackwell publisher : Blackwell publishing (2009)
18. Tatti S, Swinehart J.M, Thielert C, Tawfik H, Mescheder A, Beutner KR Sinecatechins, a defined green tea extract, in the treatment of external anogenital warts: a randomized controlled trial.*Obstet Gynecol.*; 111(6):1371. (2008)
19. Stockfleth E, Beti H, Orasan R, Grigorian F, Mescheder A, Tawfik H, Thielert C Topical Polyphenon E in the treatment of external genital and perianal warts: a randomized controlled trial. *Br J Dermatol.*; 158(6):1329.(2008)
20. Diamantis M.L, Bartlett B.L, Tyring S.K, Safety, efficacy & recurrence rates of imiquimod cream 5% for treatment of anogenital warts. *Skin Therapy Lett.* Jun; 14(5):1-3, 5 (2009)
21. Akhavan S, Mohammadi SR, Modarres - Efficacy of combination therapy of oral zinc sulfate with imiquimod, podophyllin or cryotherapy in the treatment of vulvar warts.*Journal of Obstet. and Gynae.Research* © Japan Society of Obstetrics and Gynecology Oct;40(10): 2110-3,2014.
22. RJC Gilson, J Ross, R Maw, D Rowen, ; A multicentre, randomised, double-blind, placebo controlled study of cryotherapy versus cryotherapy and podophyllotoxin cream as treatment for external anogenital warts, *Sex Transm Infect*;85:514-519 (2009)
23. Benedetti Panici, P;Scambia, G ;Baiocchi, G; Randomized Clinical Trial Comparing Systemic Interferon With Diathermocoagulation in Primary Multipleand Widespread Anogenital Condyloma. *Obstet. & Gynae.J* ,9(74) : 393-7.(1989)
24. Carrasco D ,Vander Straten M, Tyring S.K; Treatment of ano-genital warts with imiquimod 5% cream followed by surgical excision of residual lesions. *Am Acad. Dermatol.* Oct; 47(4 Suppl):S212-6. (2002)